AzTrials
AzTrials

MenopauseONTIME-CHOCNCT03949803

Eating Chocolate at the Right Time Benefits the Circadiam Sytem and Metabolic Efficiency.

A study testing Chocolate 100gr in people with Menopause, run by Universidad de Murcia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this investigation is to test the hypothesis that in humans, eating a relatively big amount of chocolate at the wrong time (bedtime) may disrupt our circadian system (change the circadian phase), while taking this same amount of chocolate in the morning (wake up condition) may synchronize it. Read more about this study

Who is it for?
Ages 45 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Menopause
What is being tested?
Chocolate 100gr
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
No sites listed yet
Study dates
1 Nov 2016to 20 Apr 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy women
  • Age: between 45 and 65 year of age
  • Caucasian
  • Menopause

Who cannot join

  • Pre-menopause women
  • Endocrine (Diabetes mellitus or others), renal, hepatic, cancer or psychiatric disorders
  • Receiving any pharmacologic treatment other than oral contraceptives
  • Bulimia diagnosis, prone to binge eating
  • Pregnancy

About this study

Official title: Effect of the Timing of Chocolate Intake on Body Fat Distribution, Substrate Oxidation, and Microbiota. Randomized, Crossover Study

The purpose of this investigation is to test the hypothesis that in humans, eating a relatively big amount of chocolate at the wrong time (bedtime) may disrupt our circadian system (change the circadian phase), while taking this same amount of chocolate in the morning (wake up condition) may synchronize it. Other related factors may be also affected such as total body weight and body fat, dietary habits (total energy intake and macronutrient distribution), the timing of food intake and of sleep, daily rhythms of TAP, microflora composition and postprandial glycemia.

Read the detailed description

Recent studies suggest that not only "what" the people eat, but also "when" the people eat may have a significant role in obesity treatment and in the regulation of the circadian system. Thus, the hypothesis of this study is eating a relatively big amount of chocolate at the wrong time, bedtime may affect:

  1. Metabolism: resting energy expenditure, corrected resting energy respiratory quotient (RQ)
  2. Glucose metabolism
  3. Total weight loss
  4. Food intake, total energy intake, and type of food
  5. Microflora (feces)
  6. Mood
  7. Disrupt our circadian system 7a) Changes in Temperature, Actimetry, and Position 7b) Electrocardiogram (ECG) 7c) Melatonin (two points) cortisol rhythm (three points) While having this same amount of chocolate in the morning (wake up condition) may synchronize it.

Other related factors may be also affected such as total body weight and body fat, dietary habits (total energy intake and macronutrient distribution), the timing of food intake and of sleep, daily rhythms of TAP, microflora composition and postprandial glycemia.

19 women (postmenopausal) following the habitual dietary habits of participants (ad libitum) will have 30% of the habitual total daily calories in chocolate of participants (Nestle, "chocolate with milk") during two consecutive weeks each under three conditions: eating chocolate within 1 hour of habitual wake-time, eating chocolate within 1 hours of habitual bedtime, or eating no chocolate. No other chocolate (i.e., none at all in control and in the washout weeks).

The protocol will be a randomized, cross-over design, with a 1-week washout between each condition.

During the 14 days in each condition, the participants will record sleep and activity schedules by dairy, food intake and food timing by phone application, daily rhythms of wrist temperature, activity and position (TAP).

Conditions
Menopause
Being tested
Chocolate 100gr
Keywords
Chocolate, Timing, Menopause, Calorimetry

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chocolate 100grBehavioural

    Evening/Night Chocolate:

    Eating 100gr of milk chocolate within 1 hours of habitual bedtime

    Control Chocolate:

    Eating no milk chocolate or other chocolate

    Chocolate Morning:

    Eating chocolate within one hour of habitual waketime.

Study groups in NCT03949803
Study groupRoleWhat they receive
Morning Chocolate, then Evening/Night Chocolate and Control ChocolateExperimentalFirst condition is eating 100gr chocolate within one hour of habitual waketime. Second condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime. Third condition is eating no milk chocolate or other chocolate.
Receives: Behavioral: Chocolate 100gr
Morning Chocolate, then Control Chocolate and Evening/Night ChocolateExperimentalFirst condition is eating 100gr chocolate within one hour of habitual waketime. Second condition is eating no milk chocolate or other chocolate. Third condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime.
Receives: Behavioral: Chocolate 100gr
Evening/Night Chocolate, then Morning Chocolate and Control ChocolateExperimentalFirst condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime. Second condition is eating 100gr chocolate within one hour of habitual waketime. Third condition is eating no milk chocolate or other chocolate.
Receives: Behavioral: Chocolate 100gr
Evening/Night Chocolate, then Control Chocolate and Morning ChocolateExperimentalFirst condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime. Second condition is eating no milk chocolate or other chocolate. Third condition is eating 100gr chocolate within one hour of habitual waketime.
Receives: Behavioral: Chocolate 100gr
Control Chocolate, then Morning Chocolate and Evening/Night ChocolateExperimentalFirst condition is eating no milk chocolate or other chocolate. Second condition is eating 100gr chocolate within one hour of habitual waketime. Third condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime.
Receives: Behavioral: Chocolate 100gr
Control Chocolate, then Evening/Night Chocolate and Morning ChocolateExperimentalFirst condition is eating no milk chocolate or other chocolate. Second condition is eating 100gr of milk chocolate within 1 hours of habitual bedtime. Third condition is eating 100gr chocolate within one hour of habitual waketime.
Receives: Behavioral: Chocolate 100gr

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Resting Energy Expenditure (Indirect Calorimetry)

    The investigators will measure by indirect calorimetry the resting energy expenditure after each condition (no chocolate, Morning Chocolate, Night Chocolate) Changes in Resting Energy Expenditure (Indirect Calorimetry) were determined by changes in resting energy expenditure occurred in the participants between baseline and after 2 weeks in each of the three different experimental conditions. Oxygen (O2) consumption (mL/min) and carbon dioxide (CO2) production (mL/min) were measured. The Respiratory Quotient (RQ) was calculated out of O2 consumption (mL/min) and CO2 production (mL/min). Energy expenditure values (kcal/day) were calculated according to the Weir equation: Metabolic rate (kcal per day) = 1440 (3.9 VO2 + 1.1 VCO2)*

    Measured: Baseline and after 2 weeks in each condition

  2. Total Body Weight

    The investigators will measure total body weight after each condition (no chocolate, Morning Chocolate, Night Chocolate)

    Measured: Baseline and after 2 weeks in each condition

Secondary outcomes (7)
  1. Fragmentation of Wrist Temperature (WT) Daily Rhythm

    The investigators will measure the fragmentation parameter derived from wrist temperature after each condition (no chocolate, Morning Chocolate, Night Chocolate). Intradaily variability (IV) characterizes the rhythm fragmentation.

    Changes in daily rhythm of wrist temperature fragmentation were measured by changes in the fragmentation parameter derived from wrist temperature along the two weeks of intervention in each of the three conditions. The participants wore a wristwatch during the last 7 days of each condition on the non-dominant wrist to record body temperature and activity. Wrist temperature parameters were measured to represent the wrist body temperature pattern, which provides an objectively measure of sleep and siesta (together with activity rhythm).

    A low fragmentation involves a low intraday rhythmicity of the circadian rhythm.

    Its values oscillated between 0, when the wave was perfectly sinusoidal, and 2, when the wave was as Gaussian noise.

    Measured: Baseline and after 2 weeks in each condition

  2. Regularity of Wrist Temperature (WT) Daily Rhythm

    The investigators will measure the regularity parameter derived from wrist temperature after each condition (no chocolate, Morning Chocolate, Night Chocolate). RegularIty is measured as interdaily stability (IS), that means rhythm stability over different days; it varied between 0 for Gaussian noise to 1 for perfect stability, where the rhythm repeated itself exactly day after day.

    Changes in daily rhythm of wrist temperature regularity were measured by changes in the regularity parameter derived from wrist temperature along the two weeks of intervention in each of the three conditions. A regular rhythm means recurring at uniform intervals. The participants wore a wristwatch during the last 7 days of each condition on the non-dominant wrist to record body temperature and activity. Wrist temperature parameters were measured to represent the wrist body temperature pattern, which provides an objectively measure of sleep and siesta (together with activity rhythm).

    Measured: Baseline and after 2 weeks in each condition

  3. Amplitude of Wrist Temperature (WT) Daily Rhythm

    The investigators will measure the amplitude parameter derived from wrist temperature after each condition (no chocolate, Morning Chocolate, Night Chocolate). In the cosinor analysis to characterize the WT rhythm, we calculate amplitude (difference between the maximum [or minimum] value of the cosine function and mesor) Changes in daily rhythm of wrist temperature amplitude were measured by changes in the amplitude parameter derived from wrist temperature along the two weeks of intervention in each of the three conditions. The participants wore a wristwatch during the last 7 days of each condition on the non-dominant wrist to record body temperature and activity. Wrist temperature parameters were measured to represent the wrist body temperature pattern, which provides an objectively measure of sleep and siesta (together with activity rhythm).

    A healthy circadian rhythm is considered as the one with high amplitude.

    Measured: Baseline and after 2 weeks in each condition

  4. Changes in Microbiota Diversity (Inverse Simpson Index)

    Microbiota diversity changes were measured using Inverse Simpson Index, accounting for both species richness (number of species) and evenness (distribution of species). A higher Inverse Simpson Index indicates greater diversity because it reduces the impact of dominant species and gives more weight to rarer species. Unlike the regular Simpson Index (which decreases as diversity increases), the inverse form is more intuitive: higher values mean a more diverse microbiota. This index is widely used in microbiome studies to compare microbial diversity across different samples, such as in health versus disease states.

    Measured: Baseline and after 2 weeks in each condition

  5. Concentration of Total Short-chain Fatty Acids (SCFAs)

    Short-chain fatty acids (SCFAs) in fecal samples were analyzed using gas-liquid chromatography (GLC) with a GC-FID system. Samples were mixed with NaOH, lyophilized, and homogenized with formic acid, methanol, and an internal standard (2-ethyl butyric acid). After ultrasonic treatment and centrifugation, the supernatant was filtered and injected into an Agilent 7890A GC system equipped with a Nukol capillary column. Helium was used as the carrier gas, and the FID temperature was set at 220°C. SCFAs were identified by comparing retention times with authentic standards, and quantification was performed using calibration curves with a high correlation (R² = 0.99). Total average values of SCFA (acetate, propionate, other minorities) in each condition were calculated.

    Measured: After 2 weeks in each condition

  6. Energy Intake

    The investigators will measure changes in total energy intake measured as kilocalories between baseline and after 2 weeks in each condition (no chocolate, Morning Chocolate, Night Chocolate) At baseline and during the 2 weeks of each condition, time-stamped photographs were captured with a cell phone app. Total energy intake during the 14 days of each condition was analyzed with the nutritional evaluation software (Grunumur 2.0 8).

    Measured: Baseline and after 2 weeks in each condition

  7. Macronutrient Composition

    The investigators will measure macronutrient composition measured as and grams per day between baseline and after 2 weeks in each condition (no chocolate, Morning Chocolate, Night Chocolate). At baseline and during the 2 weeks of each condition, time-stamped photographs were captured with a cell phone app. Macronutrient composition during the 14 days of each condition was analyzed with the nutritional evaluation software (Grunumur 2.0 8).

    Measured: Baseline and after 2 weeks in each condition

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 May 2019
  2. Study start1 Nov 2016
  3. Primary completion15 Jan 2017
  4. Study completion20 Apr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03949803
Sponsor's protocol ID
2017ES00004
Acronym
ONTIME-CHOC
Status last verified
Mar 2025
First submitted
8 Feb 2018
Last updated
15 Apr 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Hernandez-Gonzalez T, Gonzalez-Barrio R, Escobar C, Madrid JA, Periago MJ, Collado MC, Scheer FAJL, Garaulet M. Timing of chocolate intake affects hunger, substrate oxidation, and microbiota: A randomized controlled trial. FASEB J. 2021 Jul;35(7):e21649. doi: 10.1096/fj.202002770RR.

    PubMed 34164846

Questions about this trial

What is this clinical trial studying?

A study testing Chocolate 100gr in people with Menopause, run by Universidad de Murcia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Apr 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Resting Energy Expenditure (Indirect Calorimetry) (time frame: Baseline and after 2 weeks in each condition). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03949803, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in